Multiple Myeloma Hub continues to enhance global knowledge of myeloma throughout 2021

Press Release: Available for Immediate Release

The Multiple Myeloma Hub, run by Scientific Education Support (SES) in partnership with the European School of Haematology (ESH), has continued to promote significant developments in the treatment and research of multiple myeloma (MM) throughout Quarter 2 of 2021.

In addition to this activity, the Multiple Myeloma Hub has also welcomed Pfizer onto their panel of supporters. This additional financial support helps the Multiple Myeloma Hub drive the hub’s goals of providing the latest evidence-based information for novel therapeutics, strategies for disease management, expert opinions, and international congress coverage.

Speaking about the success of the Multiple Myeloma Hub’s activity, Mia Hill, IME director at Scientific Education Support, said:

“We are delighted with the progress made by the Multiple Myeloma Hub during 2021. In April, the Multiple Myeloma Hub virtually attended the ESH 3rd ‘How to Diagnose and Treat Multiple Myeloma’ to identify new diagnostics, therapeutics, and disease management approaches for patients with MM. Topics we focused on included risk stratification and risk-based therapies in MM, new developments in immunotherapies, such as genome-based targeted immunotherapy, CAR T-cells, and bi- and tri-specific antibodies.

The Multiple Myeloma Hub were also invited to provide coverage for the 7th World Congress on Controversies in Multiple Myeloma (COMy) in May, giving us the opportunity to keep the hub’s audience up to date on the most popular topics from this congress, which included information about outcomes of clinical trials on novel drug combinations, drug resistance, toxicities, and MM management in young- and older-aged patients. The first Multiple Myeloma Hub Satellite Symposium was also held this quarter, and we were thrilled with the success of the event, which was ranked as one of the Top 10 sessions at COMy, with over 700 medical professionals in attendance.”

During COMy 2021, the Multiple Myeloma Hub also spoke with María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES, and asked “should cure be the goal for MM?” Mateos outlined a roadmap to achieve a cure, including novel agents, assessments to evaluate treatment efficacy, early detection and intervention, and risk stratification to guide treatment.

This was followed by the hub’s huge success in covering the 2021 ASCO Annual Meeting in early June. The most interesting areas of clinical research highlighted in this meeting included the implications and efficacy of sensitive diagnostic tools in MM, targeted therapies, updates on ongoing clinical trials for combination drug therapies, and the impact of treatment on patients’ quality of life.

Discussing the hub’s reporting on the 26th Congress of the European Hematology Association (EHA2021), Mia Hill said:

“Reporting at such a prestigious congress enabled us to share the opinions of experts in the field, covering translational research, new treatments, and diagnostic strategies. A major focus was on adapting tailored approaches and patient-specific regimens for successful outcomes. This quarter, we also held a virtual meeting with the members of our prestigious steering committee, which allowed us to determine more robust and valuable scientific content that will be added to the Multiple Myeloma Hub.”

We are extremely grateful to all our supporters who have helped us achieve this success throughout 2021, and we are delighted to welcome Pfizer to our supporter group.”

For more information on the Multiple Myeloma Hub, please visit multiplemyelomahub.com. For media enquiries or to explore collaboration opportunities, please contact or myeloma, also known as myeloma, is a type of bone marrow cancer. Bone marrow is the spongy tissue at the centre of some bones that produces the body's blood cells. It's called multiple myeloma as the cancer often affects several areas of the body, such as the spine, skull, pelvis, and ribs.

SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our ‘KNOW’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.

Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology, which includes the Lymphoma Hub, AML Hub, ALL Hub, GvHD Hub, MPN Hub, and MDS Hub.

About the European School of Haematology (ESH)

The European School of Haematology (ESH) is a not-for-profit institution for the dissemination of information and lifelong learning founded in 1985 to promote and facilitate access to state-of-the-art and cutting-edge knowledge in haematology and related disciplines at the European level. ESH conferences present the latest science and insight into new developments in the fields of basic, clinical, and therapeutic research in haematology.

The Multiple Myeloma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MM. Our aim is to enhance knowledge on MM through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.

The Multiple Myeloma Hub is the solution for a time-stretched HCP to easily access impactful information that expedites learning and empowers their treatment decisions. Informed by patients, curated by world leaders, and endorsed by expert societies the Multiple Myeloma Hub supports HCPs worldwide.

The Multiple Myeloma Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.

The Multiple Myeloma Hub was founded in partnership with ESH in 2017.

Funding for our hubs are made possible through financial support from the pharmaceutical industry. ​All content is developed by SES in collaboration with an expert Steering Committee.​All content is independent, and the educational supporters are allowed no influence on the content.​

If you are interested in becoming a Multiple Myeloma Hub supporter, please contact